Risk stratification of patients with TP53-mutated myeloproliferative neoplasms

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• TP53 mutations in myeloproliferative neoplasms (MPN) are linked to increased leukemia transformation risk.
• However, not all MPN patients with TP53 mutations progress, necessitating better risk stratification.
• Accurate prognostication is crucial for managing MPN and TP53-mutated patients.

Purpose of the Study:

• To develop a refined risk stratification model for MPN patients with TP53 mutations.
• To identify key factors influencing overall survival (OS) in this patient cohort.
• To improve clinical decision-making for TP53-mutated MPN management.

Main Methods:

• Analysis of data from 1540 MPN patients across four specialized cancer centers.
• Multivariable analysis to identify prognostic factors for OS in TP53-mutated MPN.
• Development and validation of a risk scoring system based on identified variables.

Main Results:

• Bone marrow fibrosis, multi-hit TP53 mutation status, and higher PHANTM score were associated with worse OS.
• A risk model was developed, stratifying patients into high, intermediate, and low-risk groups.
• Median OS varied significantly: 0.5 years (high-risk), 2.3 years (intermediate-risk), and 6.3 years (low-risk).

Conclusions:

• A novel scoring system effectively refines risk stratification for TP53-mutated MPN patients.
• This model aids in identifying high-risk individuals needing closer monitoring and tailored treatment.
• The findings support improved prognostication and management strategies for chronic phase MPN with TP53 aberrations.